---
id: 226
title: Surgical Site Infection (SSI)
category: clinical_syndromes
subcategory: healthcare_associated
tags: [SSI, surgical-site-infection, wound-infection, prophylaxis, cefazolin]
difficulty: medium
---

## Question

How are surgical site infections managed? Use **"Superficial: Local Care + Oral Antibiotics, Deep/Organ-Space: IV Antibiotics + Source Control"** framework.

## Answer

### **Classification (CDC):**

**Superficial Incisional SSI (Within 30 Days):**
- **Involves skin/subcutaneous tissue** only
- **Purulent drainage, erythema, warmth, pain**

**Deep Incisional SSI (Within 30-90 Days):**
- **Involves fascia/muscle layers**
- **Purulent drainage from deep incision, dehiscence, abscess**

**Organ/Space SSI (Within 30-90 Days):**
- **Involves organs/spaces** manipulated during surgery (e.g., intra-abdominal abscess after bowel surgery)

### **Microbiology:**

**General:**
- ***Staphylococcus aureus*** (MSSA/MRSA) - most common
- **Coagulase-negative staphylococci** (CoNS)
- ***Streptococcus* species**

**Colorectal/GI Surgery:**
- **Polymicrobial** (Gram-negatives + anaerobes)
- ***E. coli*, *Bacteroides fragilis*, *Enterococcus***

**Cardiac/Vascular Surgery:**
- ***S. aureus*, CoNS**

### **Diagnosis:**

**Clinical:**
- **Superficial:** Purulent drainage, erythema, warmth, tenderness, dehiscence
- **Deep:** Fever, systemic symptoms, deep tenderness, wound dehiscence

**Culture:**
- **Wound drainage/tissue culture** (NOT swab if possible)
- **Blood cultures** (if systemic symptoms)

**Imaging (If Deep/Organ-Space):**
- **CT/ultrasound:** Detect abscess, fluid collection

### **Prevention:**

**Preoperative:**
- **Skin antisepsis:** Chlorhexidine-alcohol (preferred) OR povidone-iodine
- **Antibiotic prophylaxis:** Within 60 min of incision (120 min if vancomycin/fluoroquinolone)
  - **Clean (non-GI):** Cefazolin 2g IV × 1
  - **Colorectal:** Cefazolin + metronidazole OR cefoxitin OR ertapenem
  - **MRSA colonization:** Add vancomycin
- **Glucose control:** Target <180 mg/dL (reduces SSI)
- **Nasal decolonization:** Mupirocin (if known *S. aureus* carrier)

**Intraoperative:**
- **Normothermia** (avoid hypothermia, ↑SSI)
- **Appropriate oxygenation**
- **Hair removal:** Clippers (NOT razors)

**Postoperative:**
- **Sterile dressing × 24-48h**

### **Treatment:**

**Superficial Incisional SSI:**

**Management:**
- **Open wound, express purulent material**
- **Local wound care** (saline irrigation, dressing changes)

**Antibiotics (If Surrounding Cellulitis, Systemic Symptoms, Immunocompromised):**
- **Cephalexin 500mg PO QID × 5-7 days**
- **Dicloxacillin 500mg PO QID**
- **If MRSA:** TMP-SMX DS BID OR doxycycline 100mg BID

**Deep Incisional / Organ-Space SSI:**

**Management:**
- **Source control:** Drainage (percutaneous or surgical), debridement
- **IV antibiotics** (empiric until culture results)

**Empiric Antibiotics:**

**Clean (Cardiac, Orthopedic, Vascular):**
- **Vancomycin 15-20 mg/kg IV q8-12h** (cover MRSA)
- **Add Gram-negative coverage** if septic: Ceftriaxone, cefepime, pip-tazo

**Colorectal/GI Surgery:**
- **Pip-tazo 3.375-4.5g IV q6-8h** OR **meropenem 1g IV q8h**
- **If MRSA risk:** Add vancomycin

**Duration:**
- **Superficial:** 5-7 days (oral)
- **Deep/organ-space:** 7-14 days (IV initially, oral step-down if improving)
- **Longer if:** Osteomyelitis, inadequate source control

### **Pathogen-Specific Treatment:**

***S. aureus* (MSSA):**
- **Nafcillin 2g IV q4h** OR **cefazolin 2g IV q8h**

***S. aureus* (MRSA):**
- **Vancomycin 15-20 mg/kg IV q8-12h**

**Polymicrobial (GI Surgery):**
- **Narrow based on culture** (pip-tazo, ceftriaxone + metronidazole)

### **Complications:**

- **Wound dehiscence**
- **Necrotizing fasciitis** (see separate card)
- **Sepsis**
- **Prolonged hospitalization**

### **Special Situations:**

**Prosthetic Implants (Cardiac Devices, Mesh, Orthopedic Hardware):**
- **Early (<3 months):** *S. aureus*, Gram-negatives
- **Late (>3 months):** CoNS
- **Often requires device removal** for cure

**Sternotomy/Mediastinitis:**
- **Vancomycin + pip-tazo** (cover MRSA + Gram-negatives)
- **Surgical debridement** essential
- **High mortality** (10-20%)

## Key Points

### **Classification:**
- **Superficial:** Skin/subcutaneous
- **Deep:** Fascia/muscle
- **Organ-space:** Organs manipulated during surgery

### **Superficial = Local Care + Oral Antibiotics:**
- **Open wound, express pus**
- **Cephalexin 500mg QID × 5-7 days** (if cellulitis)

### **Deep/Organ-Space = IV + Source Control:**
- **Drainage (percutaneous or surgical)**
- **Vancomycin** (clean) OR **pip-tazo/meropenem** (GI surgery)

### **Prevention = Antibiotic Prophylaxis:**
- **Cefazolin 2g IV × 1** (within 60 min of incision)
- **Colorectal:** Cefazolin + metronidazole

### ***S. aureus* Most Common:**
- **MRSA risk:** Vancomycin
- **MSSA:** Nafcillin, cefazolin

### **Clinical Pearls:**
- **Superficial:** Open wound + local care (± cephalexin if cellulitis)
- **Deep/organ-space:** Source control + IV antibiotics (vancomycin OR pip-tazo/meropenem)
- **Prophylaxis:** Cefazolin 2g IV × 1 (within 60 min), cefazolin + metronidazole (colorectal)
- ***S. aureus* most common** (MRSA coverage if risk factors)
- **Prosthetic implants:** Often require device removal for cure

## Sources

- [CDC: Surgical Site Infection Guidelines 2024]
- [IDSA: Skin and Soft Tissue Infection Guidelines 2024]

## Media

N/A
